{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T07:02:52Z","timestamp":1794466972686,"version":"4.9.1"},"reference-count":33,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"9","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Germline loss-of-function (LoF) DDX41 variants predispose to late-onset hematopoietic malignancies (HM), predominantly of myeloid lineage. Among 43 families with germline DDX41LoF variants, bone marrow (BM) biopsies in those without (N=8) or with malignancies (N=21) revealed mild dysplasia in peripheral blood (57%) and BM (88%), long before the average age of DDX41-related HM onset. Therefore, we recommend baseline BM biopsies in people with germline DDX41LoF alleles to avoid over-diagnosis of myelodysplastic syndromes. A variety of solid tumors were also observed in our cohort, with 24% penetrance by age 75. Although acquired DDX41 mutations are common in HM, we failed to identify such alleles in solid tumors arising in those with germline DDX41LoF variants (N=15), suggesting an alternative mechanism driving solid tumor development. Furthermore, 33% of pedigrees in which \u226515% of first-degree relatives including the proband were diagnosed with a solid tumor had second germline deleterious variants in other cancer-predisposition genes, likely serving as primary cancer drivers. Finally, both lymphoblastoid cell lines and primary peripheral blood from individuals with germline DDX41LoF variants exhibited differential levels of inflammation-associated proteins. These data provide evidence of inflammatory dysfunction mediated by germline DDX41LoF alleles that may contribute to solid tumor growth in the context of additional germline cancer- associated variants. For those with HM and personal\/family histories of solid tumors, we recommend broad germline testing. DDX41 may be an indirect modifier of solid tumor pathogenesis compared to its tumor suppressor function within hematopoietic tissues, a hypothesis that can be addressed in future work.<\/jats:p>","DOI":"10.3324\/haematol.2024.286887","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T03:28:00Z","timestamp":1739417280000},"page":"2076-2090","source":"Crossref","is-referenced-by-count":7,"title":["Overall cancer risk in people with deleterious germline &lt;i&gt;DDX41&lt;\/i&gt; variants"],"prefix":"10.3324","volume":"110","author":[{"given":"Sophia C.","family":"Korotev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason X.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogameenakshi","family":"Haribabu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Strauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salina","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin","family":"Koppayi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melody","family":"Perpich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeline","family":"Pies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Moma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aelin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatice","family":"Basdag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtnee","family":"Rodgers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satyajit","family":"Kosuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryunosuke","family":"Saiki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Makishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjukta","family":"Tawde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelly","family":"Galasinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Kandikatla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hari Prasanna","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kehan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghao","family":"Bi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona","family":"Mohammadhosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seishi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupriya","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soma","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"78712","doi-asserted-by":"crossref","unstructured":"Arber DA, Orazi A, Hasserjian RP. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022; 140(11):1200-1228.","DOI":"10.1182\/blood.2022015850"},{"key":"78713","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"78714","doi-asserted-by":"crossref","unstructured":"Khoury JD, Solary E, Abla O. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms. Leukemia. 2022; 36(7):1703-1719.","DOI":"10.1038\/s41375-022-01613-1"},{"key":"78715","doi-asserted-by":"crossref","unstructured":"Makishima H, Bowman TV, Godley LA. DDX41-associated susceptibility to myeloid neoplasms. Blood. 2023; 141(13):1544-1552.","DOI":"10.1182\/blood.2022017715"},{"key":"78716","doi-asserted-by":"crossref","unstructured":"Polprasert C, Schulze I, Sekeres MA. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell. 2015; 27(5):658-670.","DOI":"10.1016\/j.ccell.2015.03.017"},{"key":"78717","doi-asserted-by":"crossref","unstructured":"Lewinsohn M, Brown AL, Weinel LM. Novel germ line DDX41 mutations define families with a lower age of MDS\/AML onset and lymphoid malignancies. Blood. 2016; 127(8):1017-1023.","DOI":"10.1182\/blood-2015-10-676098"},{"key":"78718","doi-asserted-by":"crossref","unstructured":"Kadono M, Kanai A, Nagamachi A. Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia. Exp Hematol. 2016; 44(8):745-754.e4.","DOI":"10.1016\/j.exphem.2016.04.017"},{"key":"78719","doi-asserted-by":"crossref","unstructured":"Sebert M, Passet M, Raimbault A. Germline DDX41 mutations define a significant entity within adult MDS\/AML patients. Blood. 2019; 134(17):1441-1444.","DOI":"10.1182\/blood.2019000909"},{"key":"78720","doi-asserted-by":"crossref","unstructured":"Quesada AE, Routbort MJ, DiNardo CD. DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019; 94(7):757-766.","DOI":"10.1002\/ajh.25486"},{"key":"78721","doi-asserted-by":"crossref","unstructured":"Bannon SA, Routbort MJ, Montalban-Bravo G. Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations. Front Oncol. 2021; 10:582213.","DOI":"10.3389\/fonc.2020.582213"},{"key":"78722","doi-asserted-by":"crossref","unstructured":"Goyal T, Tu ZJ, Wang Z, Cook JR. Clinical and Pathologic Spectrum of DDX41-mutated hematolymphoid neoplasms. Am J Clin Pathol. 2021; 156(5):829-838.","DOI":"10.1093\/ajcp\/aqab027"},{"key":"78723","doi-asserted-by":"crossref","unstructured":"Wan Z, Han B. Clinical features of DDX41 mutation-related diseases: a systematic review with individual patient data. Ther Adv Hematol. 2021; 12:20406207211032433.","DOI":"10.1177\/20406207211032433"},{"key":"78724","doi-asserted-by":"crossref","unstructured":"Alkhateeb HB, Nanaa A, Viswanatha D. Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms. Blood Adv. 2022; 6(2):528-532.","DOI":"10.1182\/bloodadvances.2021005738"},{"key":"78725","doi-asserted-by":"crossref","unstructured":"Li P, Brown S, Williams M. The genetic landscape of germline DDX41 variants predisposing to myeloid neoplasms. Blood. 2022; 140(7):716-755.","DOI":"10.1182\/blood.2021015135"},{"key":"78726","doi-asserted-by":"crossref","unstructured":"Li P, White T, Xie W. AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome. Leukemia. 2022; 36(3):664-674.","DOI":"10.1038\/s41375-021-01404-0"},{"key":"78727","doi-asserted-by":"crossref","unstructured":"Feurstein S, Trottier AM, Estrada-Merly N. Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages. Blood. 2022; 140(24):2533-2548.","DOI":"10.1182\/blood.2022015790"},{"key":"78728","doi-asserted-by":"crossref","unstructured":"Makishima H, Saiki R, Nannya Y. Germline DDX41 mutations define a unique subtype of myeloid neoplasms. Blood. 2023; 141(5):534-549.","DOI":"10.1182\/blood.2022018221"},{"key":"78729","doi-asserted-by":"crossref","unstructured":"Weinreb JT, Ghazale N, Pradhan K. Excessive R-loops trigger an inflammatory cascade leading to increased HSPC production. Dev Cell. 2021; 56(5):627-640.","DOI":"10.1016\/j.devcel.2021.02.006"},{"key":"78730","doi-asserted-by":"crossref","unstructured":"Chlon TM, Stepanchick E, Hershberger CE. Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia. Cell Stem Cell. 2021; 28(11):1966-1981.e6.","DOI":"10.1016\/j.stem.2021.08.004"},{"key":"78731","doi-asserted-by":"crossref","unstructured":"Mosler T, Conte F, Longo GMC. R-loop proximity proteomics identifies a role of DDX41 in transcription-associated genomic instability. Nat Commun. 2021; 12(1):7314.","DOI":"10.1038\/s41467-021-27530-y"},{"key":"78732","doi-asserted-by":"crossref","unstructured":"Weinreb JT, Gupta V, Sharvit E, Weil R, Bowman TV. Ddx41 inhibition of DNA damage signaling permits erythroid progenitor expansion in zebrafish. Haematologica. 2022; 107(3):644-654.","DOI":"10.3324\/haematol.2020.257246"},{"key":"78733","doi-asserted-by":"crossref","unstructured":"Saygin C, Roloff G, Hahn CN. Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies. Blood Adv. 2023; 7(4):549-554.","DOI":"10.1182\/bloodadvances.2022008172"},{"key":"78734","doi-asserted-by":"crossref","unstructured":"Singh RS, Vidhyasagar V, Yang S. DDX41 is required for cGAS-STING activation against DNA virus infection. Cell Rep. 2022; 39(8):110856.","DOI":"10.1016\/j.celrep.2022.110856"},{"key":"78735","doi-asserted-by":"crossref","unstructured":"Kraft IL, Godley LA. Identifying potential germline variants from sequencing hematopoietic malignancies. Blood. 2020; 136(22):2498-2506.","DOI":"10.1182\/blood.2020006910"},{"key":"78736","doi-asserted-by":"crossref","unstructured":"Guidugli L, Johnson AK, Alkorta-Aranburu G. Clinical utility of gene panel-based testing for hereditary myelodysplastic syndrome\/acute leukemia predisposition syndromes. Leukemia. 2017; 31(5):1226-1229.","DOI":"10.1038\/leu.2017.28"},{"key":"78737","doi-asserted-by":"crossref","unstructured":"Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Gen Med. 2015; 17(5):405-424.","DOI":"10.1038\/gim.2015.30"},{"key":"78738","doi-asserted-by":"crossref","unstructured":"Kadri S, Long BC, Mujacic I. Clinical validation of a next-generation sequencing genomic oncology panel via cross-platform benchmarking against established amplicon sequencing assays. J Mol Diagn. 2017; 19(1):43-56.","DOI":"10.1016\/j.jmoldx.2016.07.012"},{"key":"78739","doi-asserted-by":"crossref","unstructured":"Sun BB, Chiou J, Traylor M. Plasma proteomic associations with genetics and health in the UK Biobank. Nature. 2023; 622(7982):329-338.","DOI":"10.1038\/s41586-023-06592-6"},{"key":"78740","doi-asserted-by":"crossref","unstructured":"Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res. 2010; 20(1):24-33.","DOI":"10.1038\/cr.2009.137"},{"key":"78741","doi-asserted-by":"crossref","unstructured":"Cheloor Kovilakam S, Gu M, Dunn WG. Prevalence and significance of DDX41 gene variants in the general population. Blood. 2023; 142(14):1185-1192.","DOI":"10.1182\/blood.2023020209"},{"key":"78742","doi-asserted-by":"crossref","unstructured":"Dunphy G, Flannery SM, Almine JF. Non-canonical activation of the DNA sensing Adaptor STING by ATM and IFI16 mediates NF-kB signaling after nuclear DNA damage. Mol Cell. 2018; 71(5):745-760.e5.","DOI":"10.1016\/j.molcel.2018.07.034"},{"key":"78743","doi-asserted-by":"crossref","unstructured":"Ishikawa H, Barber GN. The STING pathway and regulation of innate immune signaling in response to DNA pathogens. Cell Mol Life Sci. 2011; 68(7):1157-1165.","DOI":"10.1007\/s00018-010-0605-2"},{"key":"78744","doi-asserted-by":"crossref","unstructured":"Hu X, Li J, Fu M, Zhao X, Wang W. The JAK\/STAT signaling pathway: from bench to clinic. Signal Transduct Target Ther. 2021; 6(1):402.","DOI":"10.1038\/s41392-021-00791-1"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/11945\/78077","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11945\/78736","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11945\/78077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:08:11Z","timestamp":1794046091000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/11945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":33,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2024.286887","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,13]]}}}